Vercirnon sodium

• CAT Number: I038007
• CAS Number: 886214-18-2
• Molecular Formula: C22H20ClN2NaO4S
• Molecular Weight: 466.91
• Purity: ≥95%
• Synonyms: sodium;(E)-[(6E)-6-(4-tert-butylphenyl)sulfonylimino-3-chlorocyclohexa-2,4-dien-1-ylidene]-(1-oxidopyridin-1-ium-4-yl)methanolate
• IUPAC Name: sodium;(4-tert-butylphenyl)sulfonyl-[4-chloro-2-(1-oxidopyridin-1-ium-4-carbonyl)phenyl]azanide
• InChI: InChI=1S/C22H21ClN2O4S.Na/c1-22(2,3)16-4-7-18(8-5-16)30(28,29)24-20-9-6-17(23)14-19(20)21(26)15-10-12-25(27)13-11-15;/h4-14H,1-3H3,(H,24,26);/q;+1/p-1
• InChIKey: RWWYDQSZJIFTES-UHFFFAOYSA-M
• SMILES: CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)[N-]C2=C(C=C(C=C2)Cl)C(=O)C3=CC=[N+](C=C3)[O-].[Na+]

Vercirnon sodium（Cat No.:I038007）is the sodium salt form of vercirnon (also known as GSK1605786), an orally bioavailable antagonist of the chemokine receptor CCR9. CCR9 plays a key role in the migration of inflammatory cells to the gastrointestinal tract, particularly in Crohn’s disease. By blocking CCR9, vercirnon sodium aims to reduce intestinal inflammation and immune cell infiltration. It was developed as a targeted therapy for inflammatory bowel diseases, offering a non-immunosuppressive approach. Despite promising early results, later-stage clinical trials showed limited efficacy, and development was discontinued. It remains of interest in chemokine-targeted research.